| 1 | Sumitomo Chemical Co. Ltd.
Sumitomo Pharma Co. Ltd.
Sumitovant Biopharma Ltd.
10% Owner | 2023-03-10 09:29:56 | 45,798,176
0 | 45,798,176 | Form 13D |
| 2 | MILLENNIUM PHARMACEUTICALS INC
Takeda Pharmaceuticals U.S.A. Inc.
10% Owner | 2018-03-29 20:50:40 | 7,420,625
0 | 7,420,625 | Form 3 |
| 3 | Takeda Pharmaceuticals International AG
TAKEDA PHARMACEUTICAL CO LTD
Takeda A/S
Takeda Europe Holdings B.V.
Takeda Pharma A/S
10% Owner | 2020-01-24 06:16:37 | 3,920,625
0 | 3,920,625 | Form 13G |
| 4 | Seely Lynn
Principal Executive Officer | 2020-04-07 17:16:33 | 1,346,517
846,168 | 2,192,685 | Form 4 |
| 5 | Sablich Kim
Chief Commercial Officer | 2020-04-07 17:14:42 | 281,174
0 | 281,174 | Form 4 |
| 6 | KARBE FRANK
Principal Fin'l & Accounting | 2021-07-09 16:27:07 | 212,296
0 | 212,296 | Form 4 |
| 7 | Torti Frank
Director | 2019-08-27 16:50:56 | 58,608
0 | 58,608 | Form 4 |
| 8 | Altmeyer Mark
Director | 2018-09-04 16:44:44 | 22,500
0 | 22,500 | Form 4 |
| 9 | DeVeydt Wayne S
Director | 2017-10-20 16:46:51 | 22,500
0 | 22,500 | Form 4 |
| 10 | Sebelius Kathleen
Director | 2020-09-17 16:12:00 | 21,603
0 | 21,603 | Form 4 |
| 11 | Romeo Marianne L.
Head,Global Trans. & Risk Mgmt | 2016-10-26 20:11:12 | 14,102
0 | 14,102 | Form 3 |
| 12 | MANCHESTER KEITH S
Director | 2016-10-26 20:13:55 | 0
0 | 0 | Form 3 |
| 13 | Ramaswamy Vivek
Director | 2016-10-26 20:17:40 | 0
0 | 0 | Form 3 |
| 14 | VIKING GLOBAL INVESTORS LP
Viking Global Opportunities Illiquid Investments Sub-Master LP
Viking Global Opportunities Portfolio GP LLC
Viking Global Opportunities GP LLC
HALVORSEN OLE ANDREAS
Ott David C.
Sundheim Daniel S.
10% Owner | 2019-07-12 16:59:53 | 0
0 | 0 | Form 13D |
| 15 | QVT Associates GP LLC
QVT Fund V LP
10% Owner | 2019-07-12 16:28:55 | 0
0 | 0 | Form 4 |
| 16 | SVF Investments (UK) Ltd
SoftBank Vision Fund L.P.
SVF Holdings (UK) LLP
SVF GP (Jersey) Ltd
Former 10% Owner | 2019-07-12 19:50:26 | 0
0 | 0 | Form 4 |
| 17 | VIKING GLOBAL INVESTORS LP
Viking Global Opportunities Illiquid Investments Sub-Master LP
Viking Global Opportunities Portfolio GP LLC
Viking Global Opportunities GP LLC
HALVORSEN OLE ANDREAS
Ott David C.
Shabet Rose Sharon
Former 10% Owner | 2019-07-12 20:33:27 | 0
0 | 0 | Form 4 |
| 18 | VIKING GLOBAL PERFORMANCE LLC
Viking Global Equities LP
Viking Global Equities II LP
VGE III Portfolio Ltd.
Viking Global Equities Master Ltd.
Viking Long Fund GP LLC
Viking Long Fund Master Ltd.
HALVORSEN OLE ANDREAS
Ott David C.
Shabet Rose Sharon
Former 10% Owner | 2019-07-12 20:34:36 | 0
0 | 0 | Form 4 |
| 19 | Dexxon Holdings Ltd.
Dexcel Pharma Technologies Ltd.
Oren Dan
See remarks | 2019-07-12 16:52:12 | 0
0 | 0 | Form 4 |
| 20 | Machado Patrick
Former 10% Owner | 2019-07-16 17:31:17 | 0
0 | 0 | Form 13D |
| 21 | Lo Andrew
Former 10% Owner | 2019-07-16 17:42:17 | 0
0 | 0 | Form 13D |
| 22 | Nomura Hiroshi
Director | 2019-12-30 17:15:03 | 0
0 | 0 | Form 3 |
| 23 | Nishinaka Shigeyuki
Director | 2022-10-21 17:15:29 | 0
0 | 0 | Form 3 |
| 24 | Valente Nancy
Director | 2023-03-10 09:32:52 | 0
0 | 0 | Form 4 |
| 25 | POTTER MYRTLE S
Director | 2023-03-10 09:32:18 | 0
0 | 0 | Form 4 |
| 26 | Merendino Lauren
Chief Commercial Officer | 2023-03-10 09:31:44 | 0
0 | 0 | Form 4 |
| 27 | Mehra Uneek
Principal Financial Officer | 2023-03-10 09:31:05 | 0
0 | 0 | Form 4 |
| 28 | Marek David C
Principal Executive Officer | 2023-03-10 09:30:13 | 0
0 | 0 | Form 4 |
| 29 | Lang Matthew
General Counsel & Corp. Secy. | 2023-03-10 09:29:36 | 0
0 | 0 | Form 4 |
| 30 | Roivant Sciences Ltd.
10% Owner | 2019-12-31 16:45:46 | 0
0 | 0 | Form 4 |
| 31 | GUINAN MARK
Director | 2023-03-10 09:28:18 | 0
0 | 0 | Form 4 |
| 32 | Curran Terrie
Director | 2023-03-10 09:27:33 | 0
0 | 0 | Form 4 |
| 33 | Arjona Ferreira Juan Camilo
Chief Medical Officer | 2023-03-10 09:24:59 | 0
0 | 0 | Form 4 |
| 34 | Gulfo Adele M.
Director | 2023-03-10 09:28:58 | 0
0 | 0 | Form 4 |